GlaxoSmithKline plc and Theravance, Inc. have announced that the FDA has on 18 December 2013, approved Anoro Ellipta a combination...
GlaxoSmithKline plc and Theravance, Inc. announced that the European Medicines Agency�s (EMA) Committee for Medicinal Products for Human Use (CHMP)...
GlaxoSmithKline and Theravance, Inc. announced that the European Commission has on 8 May 2014 granted marketing authorisation for Anoro(umeclidinium/vilanterol) as...
GlaxoSmithKline plc and Theravance, Inc. announced that the Pulmonary-Allergy Drugs Advisory Committee (PADAC) to the FDA voted 11 yes to...
GlaxoSmithKline and Innoviva announced positive data from a study comparing Anoro Ellipta (umeclidinium/vilanterol 62.5mcg/25mcg; UMEC/VI) and Stiolto Respimat (tiotropium/olodaterol 5mcg/5mcg;...
Positive results from a third lung function study comparing the efficacy and safety of Anoro Ellipta (umeclidinium /vilanterol, �UMEC/VI�), from...
GlaxoSmithKline and Theravance have announced positive results from three Phase III studies of Anoro Ellipta (umeclidinium/vilanterol) in patients with Chronic...
GlaxoSmithKline and Innoviva announced the publication in the New England Journal of Medicine (NEJM) of the landmark IMPACT study, one...
ANORO ELLIPTA is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).